All companies
Bio-Techne logo

What smart money is saying about Bio-TechneUnited States flag

TECH · Healthcare · Biotechnology · Market cap $10.23B

3 funds in our archive have pitched Bio-Techne — most recently Clearbridge Mid Cap Strategy in September 2025.

Company profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Fund coverage · 3 theses

  • Clearbridge Mid Cap Strategy
    September 2025

    Bio-Techne is a high-quality growth-oriented compounder in health care, providing durable recurring revenue streams through its life sciences tools and diagnostics.

    Read the full thesis
  • Headwaters Capital
    June 2025

    Bio-Techne (TECH) is a leading life sciences reagents and instruments company with strong recurring revenue, a healthy cash position, and potential for higher growth, despite current valuation pressures due to concerns over academic funding.

    Read the full thesis
  • Polen US Small Company Growth
    March 2025

    Bio-Techne is a leading provider of life sciences tools with strong long-term growth potential driven by innovation and exposure to emerging markets like cell and gene therapy.

    Read the full thesis

Read every full thesis on Bio-Techne

Unlock all 3 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans